StemCellsInc (@StemCellsInc) header
StemCellsInc (@StemCellsInc) profile picture

A clinical stage biotech company developing neural stem cell-based therapeutics & tools for use in research & drug discovery for the central nervous system.

Newark, California
Joined June 2014
Photo by StemCellsInc (@StemCellsInc)
We are pleased that the district court decision on invalidity has been upheld. We continue to believe that our... businesswire.com/news/home/2…
StemCells, Inc. Announces Termination of Phase II Pathway Study Following Review of Data: investor.stemcellsinc.com/ph…
$STEM to Report 12-Month Cohort I Data from its Phase II Pathway Study: investor.stemcellsinc.com/ph… #SpinalCordInjury
3
4
StemCells, Inc. Announces 1-for-12 Reverse Stock Split: investor.stemcellsinc.com/ph… $STEM
1
1
$STEM to Participate in the 3rd Annual Growth Capital Expo MicroCap Investor Conference in Las Vegas, NV: investor.stemcellsinc.com/ph…
3
4
$STEM Presents Interim Results from its Phase II Pathway Study in Chronic Cervical #spinalcordinjury at #ASIA2016: investor.stemcellsinc.com/ph…
2
4
StemCells, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update: investor.stemcellsinc.com/ph… $STEM
1
1
StemCells, Inc. Announces Webcast to Discuss Fourth Quarter 2015 Financial Results investor.stemcellsinc.com/ph… $STEM
Nominate StemCells, Inc. for the New Economy Awards 2016 here theneweconomy.com/awards @NewEconomyMag $STEM
StemCells, Inc. Announces Closing of $8 Million Public Offering: investor.stemcellsinc.com/ph… $STEM
StemCells, Inc. Announces Pricing of Public Offering to Raise $8.1 Million: investor.stemcellsinc.com/ph… $STEM
StemCells, Inc. Announces Proposed Public Offering of Common Stock and Warrants: investor.stemcellsinc.com/ph… $STEM
$STEM New #SNNLive #Video #Interview with StemCells, Inc. on Stock News Now: ow.ly/YSrPp @StemCellsInc #SpinalCordInjury
1
1
$STEM featured in @StockNewsNow: Research & Development of Cell-based Therapies for the Treatment of CNS Disorders: stocknewsnow.com/commentary/…
2
1